ITGA2B and diabetes mellitus: A meta-analysis of 6 large clinical trials evaluating the effect of GP IIb/IIIa inhibitors in ACS patients showed a 22% reduction of mortality at 30 days in DM patients (n = 6458) who received GP IIb/IIIa inhibitor compared to those who did not (4.6% versus 6.2%; P = 0.007).